{
    "title": "CRASH-1",
    "link": "https://www.thebottomline.org.uk/summaries/icm/crash-1/",
    "summary": "In adults with a head injury, do early corticosteroids compared to placebo reduce death and disability?",
    "full_content": "\nTweet\nEffect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury: randomised placebo-controlled trial\nRoberts et al for the CRASH trial collaborators. Lancet 2004; 364:1321-28. doi:10.1016/S0140-6736(04)17188-2\nClinical Question\n\nIn adults with a head injury, do early corticosteroids compared to placebo reduce death and disability?\n\nDesign\n\nRandomised, controlled trial\nCentralised (21%) and non-centralised (79%) randomised concealed allocation method\nBlinding of clinicians, patients, and data analysts\nAnnual interim analyses, with unmasking only if:\n\n\u201cproof beyond reasonable doubt of a difference\u201d was found or,\nnew published data removed equipoise and uncertainty regarding corticosteroid use\n\n\nIntention-to-treat analysis\nPowered at 90% to detect 2% difference in mortality from baseline of 15%, with accepted type I error of 0.01 (chance of false positive), if 20,000 patients were recruited\n\nSetting\n\n239 hospitals from 49 countries\n\nEurope 38%, Asia 27%, South America 16%, Africa 14%, North America 4%, Oceania 1%\n\n\nApril 1999 to May 2004\n\nPopulation\n\nInclusion: adults over 16 years with head injuries, who presented within 8 hours of injury with GCS \u2264 14\nExclusion: clear indication or contraindication for steroids\n10,008 patients randomised\n\nIntervention\n\nAdministration of methylprednisolone for 48 hours\n\nLoading dose of 2 g over 1 hour in 100 ml 0.9% NaCl\nMaintenance of 0.4 g per hour for 48 hours in 20 ml per hour 0.9% NaCl\n\n\n\nControl\n\nIdentical regime of placebo\n\nOutcome\n\nPrimary outcome: unmasking of randomisation took place after 10,008 patients due to a clear difference favouring placebo for mortality at 2-weeks\n\nCorticosteroid group 21% mortality vs placebo group 18% mortality\nRelative risk 1.18 (95% CI 1.09\u20131.27; p=0.0001)\nAbsolute risk increase 3.15% (95% CI\u00a01.60%\u20134.70%; NNH 32)\n\n\nSecondary outcome: 6-month follow-up favoured placebo for mortality and severe disability\n\n\u00a0\n\nPrimary Outcome\n\n\nMeasure\nCorticosteroids\nPlacebo\nRR\nARR\nNNH\n\n\n\n\n2-week mortality\n1052 (21.1%)\n893 (17.9%)\n1.18\n(95% CI 1.09\u20131.27; p=0.0001)\n-3.15%\n(95% CI 1.60%\u20134.70%)\n31\n\n\n\n\nCI = confidence interval; p = p-value; RR = relative risk; ARR = absolute risk reduction; NNH = number-needed-to-harm.\n\n\n\n\nSecondary Outcomes\n\n\nMeasure\nCorticosteroids\nPlacebo\nRR\nARR\nNNH\n\n\n\n\n6-month mortality\n1248 (25.7%)\n1075 (22.3%)\n1.15\n(95% CI 1.07\u20131.24; p=0.0001)\n-3.40%\n(95% CI 1.70%\u20135.10%)\n29\n\n\n6-month mortality or severe disability\n1828 (38.1%)\n1728 (36.3%)\n1.05\n(95% CI 0.99\u20131.10; p=0.079)\n-1.80%\n(95% CI\u00a0-0.12%\u20133.72%)\n55\n\n\n\nAuthors\u2019 Conclusions\n\n\u201cCorticosteroids should not be used routinely to treat head injury, whatever the severity.\u201d\n\nStrengths\n\nExcellent external validity due to worldwide recruitment and minimal exclusion criteria\nRobust statistical thresholds in planning phase (\u237a<0.01, \u03b2=90%)\nPrimary outcome data available for over 99% of patients\nRapid publication of important outcome with secondary outcomes published later\n\nWeaknesses\n\nHalting at interim stage may produce results that are due to an extreme play of chance\nHyperglycaemia from corticosteroid administration may have unblinded clinicians and / or led to unbalanced management of the two groups (see Lancet comments)\nCause of death not investigated, so further theories and an explanation for the results are limited\n\n\nThe Bottom Line\n\nCorticosteroids should not be given to patients with head injuries, unless other specific indications exist that outweigh the increased risk of death demonstrated by this trial\n\n\n\nExternal Links\n\n[article abstract]\u00a0Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury: randomised placebo-controlled trial by CRASH trial collaborators\n[follow-up publication]\u00a0Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury\u2014outcomes at 6 months by CRASH trial collaborators\n[trial website]\u00a0MRC CRASH\n[editorial] A CRASH landing in severe head injury by Sauerland and Maegele\n[comments] Lancet vol 365, issue 9455 with 4 comments to CRASH\n\n\nMetadata\nSummary author: @DuncanChambler\nSummary date: 15 August 2014\nPeer-review editor:\u00a0@davidslessor\n\n\n"
}